Literature DB >> 20015873

Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium.

Marie-Marcelle Trinh-Trang-Tan1, Camilo Vilela-Lamego, Julien Picot, Marie-Paule Wautier, Jean-Pierre Cartron.   

Abstract

BACKGROUND: Abnormal adhesiveness of red blood cells to endothelium has been implicated in vaso-occlusive crisis of sickle cell disease. The present study examined whether the SAD mouse model exhibits the same abnormalities of red blood cell adhesion as those found in human sickle cell disease. DESIGN AND METHODS: The repertoire of adhesive molecules on murine erythrocytes and bEnd.3 microvascular endothelial cells was determined by flow cytometry using monoclonal antibodies or by western blotting. Adhesion was investigated in dynamic conditions and measured at different shear stresses.
RESULTS: CD36, CD47 and intercellular adhesion molecular-4, but not Lutheran blood group antigen/basal cell adhesion molecule, are present on mouse mature erythrocytes. alpha(4)beta(1) are not expressed on SAD and wild type reticulocytes. Endothelial bEnd.3 cells express alpha(V)beta(3), alpha(4)beta(1), CD47, vascular cell adhesion molecule-1, and Lutheran blood group antigen/basal cell adhesion molecule, but not CD36. Adhesion of SAD red cells is: (i) 2- to 3-fold higher than that of wild type red cells; (ii) further increased on platelet activating factor-activated endothelium; (iii) not stimulated by epinephrine; (iv) inhibited after treating the endothelium with a peptide reproducing one of the binding sequences of mouse intercellular adhesion molecular-4, or with mon-oclonal antibody against murine alpha(v) integrin; and (v) inhibited after pretreatment of red blood cells with anti-mouse CD36 monoclonal antibodies. The combination of treatments with intercellular adhesion molecular-4 peptide and anti-CD36 monoclonal antibodies eliminates excess adhesion of SAD red cells. The phosphorylation state of intercellular adhesion molecular-4 and CD36 is probably not involved in the over-adhesiveness of SAD erythrocytes.
CONCLUSIONS: Intercellular adhesion molecular-4/alpha(v)beta(3) and CD36/thrombospondin interactions might contribute to the abnormally high adhesiveness of SAD red cells. The SAD mouse is a valuable animal model for investigating adhesion processes of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015873      PMCID: PMC2864378          DOI: 10.3324/haematol.2009.017392

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  36 in total

1.  Unavailability of CD147 leads to selective erythrocyte trapping in the spleen.

Authors:  I Coste; J F Gauchat; A Wilson; S Izui; P Jeannin; Y Delneste; H R MacDonald; J Y Bonnefoy; T Renno
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

Review 2.  Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion.

Authors:  Paul S Frenette
Journal:  Microcirculation       Date:  2004-03       Impact factor: 2.628

3.  Endothelin-1 decreases CD36 protein expression in vascular smooth muscle cells.

Authors:  Ching Fai Kwok; Chi-Chang Juan; Low-Tone Ho
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-09-19       Impact factor: 4.310

4.  Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist.

Authors:  G A Lutty; M Taomoto; J Cao; D S McLeod; P Vanderslice; B W McIntyre; M E Fabry; R L Nagel
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-05       Impact factor: 4.799

5.  Novel secreted isoform of adhesion molecule ICAM-4: potential regulator of membrane-associated ICAM-4 interactions.

Authors:  Gloria Lee; Frances A Spring; Stephen F Parsons; Tosti J Mankelow; Luanne L Peters; Mark J Koury; Narla Mohandas; David J Anstee; Joel Anne Chasis
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

6.  Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor.

Authors:  D K Kaul; H M Tsai; X D Liu; M T Nakada; R L Nagel; B S Coller
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

7.  The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia.

Authors:  K Lee; P Gane; F Roudot-Thoraval; B Godeau; D Bachir; F Bernaudin; J P Cartron; F Galactéros; P Bierling
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

8.  Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.

Authors:  R P Hebbel; M A Boogaerts; J W Eaton; M H Steinberg
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

Review 9.  The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy.

Authors:  Robert P Hebbel; Raymond Osarogiagbon; Dhananjay Kaul
Journal:  Microcirculation       Date:  2004-03       Impact factor: 2.628

10.  Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion.

Authors:  Patrick C Hines; Qin Zen; Sharran N Burney; Deborah A Shea; Kenneth I Ataga; Eugene P Orringer; Marilyn J Telen; Leslie V Parise
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

View more
  9 in total

1.  Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Authors:  Marilyn J Telen; Ted Wun; Timothy L McCavit; Laura M De Castro; Lakshmanan Krishnamurti; Sophie Lanzkron; Lewis L Hsu; Wally R Smith; Seungshin Rhee; John L Magnani; Helen Thackray
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

Review 2.  Intercellular adhesion molecules (ICAMs) and spermatogenesis.

Authors:  Xiang Xiao; Dolores D Mruk; C Yan Cheng
Journal:  Hum Reprod Update       Date:  2013-01-03       Impact factor: 15.610

3.  Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.

Authors:  Sandrine Laurance; Pauline Lansiaux; François-Xavier Pellay; Michelle Hauchecorne; Arndt Benecke; Jacques Elion; Claudine Lapoumeroulie
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

Review 4.  State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Authors:  Latika Puri; Kerri A Nottage; Jane S Hankins; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

5.  Phenylethanolamine N-methyltransferase gene polymorphisms associate with crisis pain in sickle cell disease patients.

Authors:  Nilanjana Sadhu; Ellie H Jhun; Andrew Posen; Yingwei Yao; Ying He; Robert E Molokie; Diana J Wilkie; Zaijie J Wang
Journal:  Pharmacogenomics       Date:  2020-03-12       Impact factor: 2.533

6.  Influence of the Clinical Status on Stress Reticulocytes, CD 36 and CD 49d of SSFA 2 Homozygous Sickle Cell Patients Followed in Abidjan.

Authors:  Duni Sawadogo; Aïssata Tolo-Dilkébié; Mahawa Sangaré; Nelly Aguéhoundé; Hermance Kassi; Toussaint Latte
Journal:  Adv Hematol       Date:  2014-02-27

Review 7.  Red Blood Cells: Chasing Interactions.

Authors:  Virginia Pretini; Mischa H Koenen; Lars Kaestner; Marcel H A M Fens; Raymond M Schiffelers; Marije Bartels; Richard Van Wijk
Journal:  Front Physiol       Date:  2019-07-31       Impact factor: 4.566

8.  Red Blood Cells: Tethering, Vesiculation, and Disease in Micro-Vascular Flow.

Authors:  Robert J Asaro; Pedro Cabrales
Journal:  Diagnostics (Basel)       Date:  2021-05-27

9.  Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia.

Authors:  Megha Kaushal; Colleen Byrnes; Zarir Khademian; Natalie Duncan; Naomi L C Luban; Jeffery L Miller; Ross M Fasano; Emily Riehm Meier
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.